Ignite Creation Date:
2024-05-05 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00006456
Status:
COMPLETED
Last Update Posted:
2010-02-24
First Post:
2000-11-06
Brief Title:
Stereotactic Radiosurgery in Treating Patients With Liver Metastases Lung Metastases or Other Advanced Solid Tumors
Sponsor:
Virginia Commonwealth University
Organization:
Virginia Commonwealth University
Study Overview
Official Title:
Fractionated Stereotactic Body Radiosurgery for Extracranial Tumors
Status:
COMPLETED
Status Verified Date:
2010-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Stereotactic radiosurgery delivers x-rays directly to the tumor and may cause less damage to normal tissue
PURPOSE Phase II trial to study the effectiveness of stereotactic radiosurgery in treating patients who have liver metastases lung metastases or other advanced solid tumors
PURPOSE Phase II trial to study the effectiveness of stereotactic radiosurgery in treating patients who have liver metastases lung metastases or other advanced solid tumors
Detailed Description:
OBJECTIVES
Determine the feasibility of fractionated stereotactic body radiosurgery in patients with advanced extracranial tumors
Assess the toxicities of this treatment regimen in these patients
Determine tumor response and cause of death in these patients treated with this regimen
OUTLINE Patients receive fractionated stereotactic body radiosurgery over 30 minutes for 5-10 days for a total of 3 treatments
Patients are followed every 3 months
PROJECTED ACCRUAL A total of 10-25 patients will be accrued within 2-3 years
Determine the feasibility of fractionated stereotactic body radiosurgery in patients with advanced extracranial tumors
Assess the toxicities of this treatment regimen in these patients
Determine tumor response and cause of death in these patients treated with this regimen
OUTLINE Patients receive fractionated stereotactic body radiosurgery over 30 minutes for 5-10 days for a total of 3 treatments
Patients are followed every 3 months
PROJECTED ACCRUAL A total of 10-25 patients will be accrued within 2-3 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-V00-1612 | US NIH GrantContract | None | httpsreporternihgovquickSearchP30CA016059 |
| P30CA016059 | NIH | None | None |
| MCV-MCC-9812-2C | None | None | None |